Inclusion Criteria:  Adult (age ≥18 years) patients diagnosed with any subtype of stroke (first or recurrent). Medically stable, assessed by a stroke physician. Able to be enrolled between within 7 days of stroke symptom onset. Able to sit independently. Able to stand with or without assistance. Sufficient English language comprehension and cognitive ability to understand the study protocol, give informed consent and follow instructions.  Exclusion Criteria:  Autonomic nervous system disorder causing haemodynamic instability e.g. pure autonomic failure, Parkinson's disease, multiple system atrophy and Shy-Drager syndrome Lower-limb pain when standing. Restricted range of motion due to spasticity or contracture impairing ability to stand. Orthopaedic impairment (e.g. bone fracture or ligament rupture) preventing prevent full weight bearing activities. Resting systolic blood pressure ≤100 mmHg or ≥180 mmHg. Resting diastolic blood pressure ≤50 mmHg or ≥120 mmHg. Significant tachycardia ≥120 beats per minute at rest. Significant bradycardia ≤40 beats per minute at rest. Peripheral oxygen saturation ≤85% without use of supplementary oxygen. Life expectancy <6 months (terminal illness). Currently participating in another clinical trial that is likely to affect outcome measures (e.g. experimental drug that affects blood pressure or blood vessel tone). Likely to be discharged from hospital or repatriated within 48 hours of stroke onset.